Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read More
An organization builder with a track record of delivering unprecedented growth ...
Alberto joined Selexis with nearly 30 years of experience leading the...
Pierre-Alain is a graduate of the University of Lausanne, Department of...
Roland joined Selexis from Polpharma Biologics where he was head of business development, CDMO Europe.
Myriam joined Selexis in 2012 as project leader, managing and coordinating...
Ghislaine joined Selexis in July 2015 as Genomic Director responsible for...
David is director of cell line services. He is responsible for...
Séverine joined Selexis in December 2015 to lead the Cell Line...
Alexandre is Director of Molecular Biology for Selexis. Alexandre joined Selexis...
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Copyright© 2022 Selexis SA. All Rights Reserved.